Congenital hyperinsulinaemic hypoglycaemia – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:31:19 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Congenital hyperinsulinaemic hypoglycaemia – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Safety and Effects of Efpegerglucagon in Children Aged 2 and Older with Congenital Hyperinsulinism https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-efpegerglucagon-in-children-aged-2-and-older-with-congenital-hyperinsulinism/ Wed, 29 Apr 2026 14:27:35 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-efpegerglucagon-in-children-aged-2-and-older-with-congenital-hyperinsulinism/ This clinical trial is focused on studying a condition known as Congenital Hyperinsulinism (CHI). This is a rare condition where the body produces too much insulin, leading to low blood sugar levels. The trial will test a new treatment called HM15136, which is a solution for injection. The purpose of the study is to evaluate the safety and how well the body tolerates this new treatment, as well as to understand how the drug behaves in the body over time.

Participants in the study will receive the HM15136 treatment for a period of 8 weeks. During this time, researchers will monitor the participants to see how their bodies respond to the treatment. This includes checking for any side effects and measuring how the drug is processed in the body. The study will also look at how the treatment affects the frequency of low blood sugar events in participants.

The study is open-label, meaning both the researchers and participants will know that HM15136 is being administered. Participants will receive the treatment through injections under the skin. The study aims to provide valuable information on the potential benefits and risks of HM15136 for children with Congenital Hyperinsulinism, which could lead to better management of this condition in the future.

]]>